Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Formulation of IXAZOMIB (MLN9708), Administered Twice-weekly in Combination With Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment
Sponsor: Millennium Pharmaceuticals, Inc.
A PHASE1/PHASE2 clinical study on Multiple Myeloma, this trial is completed. The trial is conducted by Millennium Pharmaceuticals, Inc. and has accumulated 10 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Apr 2019 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
Jun 2018 — Apr 2019 [monthly]
Completed PHASE1_PHASE2
▶ Show 5 earlier versions
-
Mar 2018 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2017 — Mar 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Aug 2017 — Sep 2017 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Completed → Active Not Recruiting
-
Feb 2017 — Aug 2017 [monthly]
Completed PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1_PHASE2
First recorded
Oct 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Millennium Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ann Arbor, United States, Berkeley, United States, Boston, United States, Chicago, United States, Columbus, United States, Dallas, United States, Duarte, United States, Durham, United States, Fairfax, United States, Hackensack, United States and 8 more location s